Fagron (ENXTBR:FAGR) shareholders approved all resolutions at the Annual and Extraordinary General Meetings. The meetings covered a revised remuneration policy, dividend distribution, and confirmation of the CEO and CFO for new terms. The Board’s authorized capital was renewed for five years, giving the company continued flexibility for future corporate actions. Fagron operates in pharmaceutical compounding, supplying customized medications and related products. For investors following...

Fagron’s analyst story has just been refreshed with a new price target of €29, up from €28, which provides an updated reference point for what covering analysts think the shares could be worth. That €1 lift lines up with commentary that points to continued confidence in the company’s ability to meet expectations, even if the change itself is relatively modest. As you read on, you will see how this updated target fits into the broader narrative and what to watch to keep track of any further...

Fagron (ENXTBR:FAGR) has completed the acquisition of Vepakum, expanding its presence in Latin America. The deal adds new verticals and product lines to Fagron’s existing pharmaceutical compounding activities. The transaction marks a material corporate move that could influence Fagron’s long term positioning in the region. Fagron, known for its focus on pharmaceutical compounding and personalized medicine solutions, is using the Vepakum acquisition to deepen its footprint in Latin America...

Fagron (ENXTBR:FAGR) has drawn investor interest after recent share price moves, supported by reported revenue of €918.75m and net income of €85.687m. This has prompted a closer look at its valuation and business profile. See our latest analysis for Fagron. The recent 1 day share price return of 8.56% at €23.45 builds on a 90 day share price return of 13.29%, while the 3 year total shareholder return of 65.44% points to stronger long term momentum. If Fagron’s move has you thinking about what...

Wondering if Fagron at €21.30 is still a smart buy after its run up, or if the easy money has already been made? This article will walk through what the current price really implies. The stock has climbed 3.4% over the last week, 2.9% over the past month, and is now up 27.1% year to date, adding to a 68.6% gain over three years and 17.4% over five. This naturally raises the question of whether the market is now getting ahead of itself. Recent headlines have focused on Fagron's continued push...

Fagron (ENXTBR:FAGR) shares edged higher today, continuing a recent run that has seen the stock up over 4% for the past week. Investors seem to be weighing the current momentum against longer-term growth figures and valuation. See our latest analysis for Fagron. Fagron’s share price momentum is picking up pace, boosted by a strong year-to-date gain of over 25%. While the latest move caps a robust run, it comes after a brief 90-day dip. This reflects shifting investor sentiment as the market...

If you are pondering what to do with Fagron stock right now, you are far from alone. Looking at the numbers, there is a lot for investors to consider. The shares are up a striking 16.9% so far this year, with a comfortable 8.1% gain over the past twelve months. That kind of return stands out, especially when you consider the three-year performance, an impressive 71.1% rise. Of course, it's not all smooth sailing. The last month has been rough, with Fagron shares down 5.1%, and the past week...